RYCFX Mutual Fund (Rydex Biotechnology Fund Class C) is managed by Rydex Funds with $394,282.66 in net assets. RYCFX expense ratio is 2.38%, holding 76 positions across sectors including Health Care, Unknown, Materials. Inception date: 2001-03-30.

RYCFX performance shows a YTD return of 3.81%. The 1-year return is 51.64% and the 5-year return is 10.35%. RYCFX dividend yield stands at 20.94%, paid annually.

RYCFX top holdings include Abbvie Inc (8.8%), Amgen Inc. (5.3%), Gilead Sciences Inc (4.9%), Nvaesrtex Pharmaceuticals Inc (4.3%), Alnylam Pharmace (3.3%). View all RYCFX holdings, sector breakdown, or dividend history.

RYCFX can be compared against other funds using the overlap calculator or side-by-side comparison tool. RYCFX alternatives are available via the screener, along with tax-loss harvesting opportunities.